Cancer in North America: Volume Four: Cancer Survival in the United States and Canada

Transcription

1 Cancer in North America: Volume Four: Cancer Survival in the United States and Canada Seattle / Puget Sound Greater Bay Area Metro Detroit Washington D.C. Los Angeles Metro Atlanta North American Association of Central Cancer Registries, Inc.

2

3 EXECUTIVE SUMMARY Members of the North American Association of Central Cancer Registries, Inc. (NAACCR) participate voluntarily in an annual call for data to develop a multi-registry, aggregated data resource for cancer surveillance and research. NAACCR has been producing Cancer in North America (CINA) incidence and mortality publications for more than 15 years. NAACCR s Strategic Management Plan charges the NAACCR Survival Analysis Work Group (SAWG) with providing resources and guidance to NAACCR members on survival analysis-related activities, with the expected outcome of publishing cancer survival estimates on a wider population than is currently available. The SAWG has been working towards routinely generating state- and province-specific 5-year relative survival estimates for inclusion in the CINA annual reports. NAACCR s SAWG is pleased to announce the inaugural CINA Survival publication, which includes data from 41 registries on more than 6.7 million cases diagnosed among North Americans between 2005 and Beginning in 2016, CINA Survival will be published annually along with the other CINA volumes. The inaugural CINA Survival publication includes diagnosis years with follow-up through the end of Including CINA Survival, the CINA monograph is organized into four volumes: Volume One presents the aggregated cancer incidence data representing North America including data from the high quality registries in the United States and Canada. Volume Two describes the registry-specific cancer incidence rates by cancer site, sex, race, ethnicity and stage for all NAACCR members in good standing that submit data and elect to be included in the monograph. Volume Three presents the registry-specific cancer death rates by cancer site, sex, race, and ethnicity. CINA Survival, along with the other three CINA volumes and their population data, supporting appendices, and cancer rates age-adjusted to the U.S., Canadian and World population standards, are available free of charge from the NAACCR website. We hope that CINA Survival, with the monograph and companion CINA products and resources, facilitates studies of cancer burden, so that we are better able to identify and understand appropriate and important measures to control the myriad diseases within the cancer rubric. The cancer surveillance infrastructure in the United States and Canada has been orchestrated to meet these objectives. This publication is made possible by the continuing efforts of the NAACCR member registries. High quality standardized cancer data aggregated across the states, provinces, territories, and regions in North America is the direct result of their dedication to cancer surveillance. The Editors March 2016 EXECUTIVE SUMMARY i

4

5 CANCER IN NORTH AMERICA: VOLUME FOUR: CANCER SURVIVAL IN THE UNITED STATES AND CANADA A Publication of the North American Association of Central Cancer Registries, Inc. (NAACCR) Editors: Chris Johnson, Cancer Data Registry of Idaho Hannah Weir, U.S. Centers for Disease Control and Prevention Angela Mariotto, U.S. Centers for Disease Control and Prevention Diane Nishri, Cancer Care Ontario Reda Wilson, U.S. Centers for Disease Control and Prevention March 2016 The Editorial Subcommittee of the NAACCR Standing Committee, Data Use and Research Committee publishes this monograph. We are grateful to the National Cancer Institute, National Institutes of Health (NCI/NIH) for providing support for the production under Contract No. HHSN C/ADB Contract No. PC We acknowledge partial support of NAACCR staff by cooperative agreement U75/CCU from the Centers for Disease Control and Prevention (CDC) and by the NCI/NIH Contract No. HHSN C/ADB Contract No. PC Its contents are solely the responsibility of the editors and do not necessarily represent the official view of CDC. iii

6

7 CINA SURVIVAL PARTICIPANTS Seattle Puget Sound Greater Bay Area Metro Detroit Los Angeles Washington D.C. Metro Atlanta Participating Registries SUGGESTED CITATION: Johnson CJ, Weir HK, Mariotto AB, Nishri D, Wilson R (eds). Cancer in North America: Volume Four: Cancer Survival in the United States and Canada Springfield, IL: North American Association of Central Cancer Registries, Inc. March v

8 TABLE OF CONTENTS SECTION I: Introduction and Technical Notes... I-1 SECTION II: Five Year Age-Standardized Relative Survival Ratios for Cancers Diagnosed , United States, Canada and North America All Sites...II-1 Urinary Bladder...II-2 Brain & Other Nervous System...II-3 Female Breast...II-4 Cervix uteri...ii-5 Colon & Rectum...II-6 Esophagus...II-7 Kidney & Renal Pelvis...II-8 Larynx...II-9 Leukemias... II-10 Liver & Intrahepatic Bile Duct... II-11 Lung & Bronchus... II-12 Hodgkin Lymphoma... II-13 Non-Hodgkin Lymphoma... II-14 Melanoma of the Skin... II-15 Mesothelioma... II-16 Myeloma... II-17 Oral Cavity & Pharynx... II-18 Ovary... II-19 Pancreas... II-20 Prostate... II-21 Stomach... II-22 Testis... II-23 Thyroid... II-24 Corpus & Uterus, NOS... II-25 SECTION III: Five Year Age-Standardized Relative Survival Ratios for Cancers Diagnosed , by Registry and Race All Races All Sites... III-1 All Sites (Standardized)... III-2 Urinary Bladder... III-3 Brain & Other Nervous System... III-4 Female Breast... III-5 Cervix uteri... III-6 Colon & Rectum... III-7 Esophagus... III-8 Kidney & Renal Pelvis... III-9 Larynx... III-10 Leukemias... III-11 Liver & Intrahepatic Bile Duct... III-12 Lung & Bronchus... III-13 Hodgkin Lymphoma... III-14 Non-Hodgkin Lymphoma... III-15 Melanoma of the Skin... III-16 Mesothelioma... III-17 Myeloma... III-18 Oral Cavity & Pharynx... III-19 Ovary... III-20 Pancreas... III-21 Prostate... III-22 Stomach... III-23 Testis... III-24 Thyroid... III-25 Corpus & Uterus, NOS... III-26 TABLE OF CONTENTS vi

9 Contents White All Sites... III-27 All Sites (Standardized)... III-28 Urinary Bladder... III-29 Brain & Other Nervous System... III-30 Female Breast... III-31 Cervix uteri... III-32 Colon & Rectum... III-33 Esophagus... III-34 Kidney & Renal Pelvis... III-35 Larynx... III-36 Leukemias... III-37 Liver & Intrahepatic Bile Duct... III-38 Lung & Bronchus... III-39 Hodgkin Lymphoma... III-40 Non-Hodgkin Lymphoma... III-41 Melanoma of the Skin... III-42 Mesothelioma... III-43 Myeloma... III-44 Oral Cavity & Pharynx... III-45 Ovary... III-46 Pancreas... III-47 Prostate... III-48 Stomach... III-49 Testis... III-50 Thyroid... III-51 Corpus & Uterus, NOS... III-52 Black All Sites... III-53 All Sites (Standardized)... III-54 Urinary Bladder... III-55 Brain & Other Nervous System... III-56 Female Breast... III-57 Cervix uteri... III-58 Colon & Rectum... III-59 Esophagus... III-60 Kidney & Renal Pelvis... III-61 Larynx... III-62 Leukemias... III-63 Liver & Intrahepatic Bile Duct... III-64 Lung & Bronchus... III-65 Hodgkin Lymphoma... III-66 Non-Hodgkin Lymphoma... III-67 Melanoma of the Skin... III-68 Mesothelioma... III-69 Myeloma... III-70 Oral Cavity & Pharynx... III-71 Ovary... III-72 Pancreas... III-73 Prostate... III-74 Stomach... III-75 Testis... III-76 Thyroid... III-77 Corpus & Uterus, NOS... III-78 TABLE OF CONTENTS vii

10

11 Section I Introduction and Technical Notes Seattle Puget Sound Greater Bay Area Metro Detroit Los Angeles Washington D.C. Metro Atlanta Participating Registries

12

13 NAACCR Cancer in North America (CINA) Survival Introduction and Technical Notes The NAACCR Survival Analysis Work Group is pleased to present the inaugural CINA Survival publication that includes data from 41 registries on more than 6.7 million cases diagnosed among North Americans between 2005 and Beginning in 2016, CINA Survival will be published annually along with the other CINA volumes. Volume Four is comprised of two data sections: Section two includes counts, relative survival ratios and confidence intervals for the United States, Canada and North America combined. These statistics are presented for all races by sex and select cancer sites. The tables for each cancer site present statistics by a total, stage and specific age groups for each region. In the United States combined, statistics by white and black are also available. Section three includes counts, relative survival ratios and confidence intervals by registry, sex and select cancer sites. Survival statistics are available for the U.S. and Canadian registries by all races and for the U.S. registries by white and black. NAACCR Survival Analysis Work Group Members: Hyunsoon Cho, U.S. National Cancer Institute Meena Patil, Oregon State Cancer Registry Larry Ellison, Statistics Canada Paulo Pinheiro, University of Nevada, Las Vegas Monique Hernandez, Florida Cancer Data System Baozhen Qiao, New York State Cancer Registry Bin Huang, Kentucky Cancer Registry Lorraine Shack, Cancer Control Alberta *Deb Hurley, South Carolina Central Cancer Registry Trevor Thompson, U.S. Centers for Disease Control and Prevention *Chris Johnson, Cancer Data Registry of Idaho Donna Turner, Canadian Partnership Against Cancer Angela Mariotto, U.S. National Cancer Institute Hannah Weir, U.S. Centers for Disease Control and Prevention Cyllene Morris, California Cancer Registry Ted Williamson, Oncolog Diane Nishri, Cancer Care Ontario Reda Wilson, U.S. Centers for Disease Control and Prevention Xiaoling Niu, New Jersey State Cancer Registry Diana Withrow, Cancer Care Ontario David O'Brien, Alaska Cancer Registry Kevin Zhang, ICF International * Co-chairs. The NAACCR Survival Analysis Work Group dedicates the inaugural CINA Survival publication to the memory Xiaoling Niu, MS who worked tirelessly on this effort and many editions of Cancer in North America. She was a valuable contributor to the field of cancer surveillance and her dedication and brilliance are sorely missed. Special thanks go to Steve Scoppa and Rick Firth, Information Management Services, Inc., who prepared the analytic dataset used for this report, and all of the registry staff who contributed data and reviewed preliminary results. INTRODUCTION AND TECHNICAL NOTES I-1

14 Cancer in North America: Survival INTRODUCTION The North American Association of Central Cancer Registries (NAACCR) has been producing Cancer in North America (CINA) incidence and mortality publications for over 15 years. Along with incidence and mortality data, information on population-based cancer survival is necessary to understand the burden of cancer. NAACCR s Strategic Management Plan charges the NAACCR Survival Analysis Work Group (SAWG) with providing resources and guidance to NAACCR members on survival analysis-related activities, with the expected outcome of publishing cancer survival estimates on a wider population than is currently available. The SAWG is working towards routinely generating state- and province-specific 5-year relative survival estimates for inclusion in the CINA annual reports. TECHNICAL NOTES Registry Inclusion. For registries to be included in CINA Survival, they needed to: (1) provide active consent, (2) meet CINA incidence criteria for all relevant years, and (3) either meet the SEER standards for follow-up 1 or ascertain deaths through the study cutoff date (December 31, 2011). For the November 2014 Call for Data, the publication of survival estimates in CINA was included as a Secondary Use of Data requiring active consent from registries. To meet the SEER standard for follow-up, a minimum of 90% of patients needed to have follow-up dates on or after January 1, 2012, or be deceased. These follow-up dates could have been the result of either passive or active patient follow-up mechanisms. 2 We used the November 2014 Call for Data file to measure the follow-up rate and the vital status follow-up activities form that is part of the annual call for data to learn what registries performed to ascertain deaths. For U.S. registries that did not meet the SEER standard for follow-up, it was necessary to conduct state death linkages and linkage with the National Death Index. For Canadian registries, it was necessary to conduct death linkages within the province or territory. National death clearance in Canada is on hold pending legal agreements among the provinces and Statistics Canada, which impacts follow-up for 2009 and later. However, because the number of deaths that occur out of province is a small proportion of total deaths, we believe that Canadian survival data are negligibly influenced by the lack of national death linkage. The inaugural CINA Survival publication includes diagnosis years with follow-up through the end of Using information from the NAACCR Call for Data Follow-Up Activities Forms, follow-up through 2011 was deemed to be the best balance between including the most current data and including the most registries. In terms of national coverage, CINA Survival includes data from 8 of 13 Canadian provinces/territories, 28 of 51 states/district of Columbia, and the Detroit and Seattle-Puget Sound Metropolitan Area SEER registries. National population coverage by CINA Survival is about 62% for the United States and 63% for Canada. The NAACCR U.S. combined and NAACCR Canadian combined statistics may not be representative of the total national populations. NAACCR North American survival statistics are a combination of U.S. and Canadian data. Data from 41 state, sub-state, and provincial registries are included in the registry-specific tables. To avoid double counting, data from sub-state registries in California and Georgia were not included in the NAACCR U.S. combined or NAACCR North American statistics. The sub-state registries in California and Georgia were included in the registry-specific statistics. I-2 INTRODUCTION AND TECHNICAL NOTES

15 Statistical Methods. Relative survival is a measure of excess mortality experienced by cancer patients. It is calculated by dividing the observed survival from all causes of death for the patient cohort by the expected survival in a comparable group not diagnosed with cancer as estimated by life tables. Relative survival is based on the assumption of independent competing causes of death. It is a theoretical population-based measure representing cancer survival in the absence of other causes of death. Relative survival is useful as a policy statistic for comparing over time or between different geographic areas. For CINA Survival, we included malignant cases per the SEER behavior recode for analysis 3 aged at diagnosis during with follow-up/death ascertainment through the study cutoff date of December 31, a Cases reported solely via death certificates or autopsy were excluded. For registries conducting active follow-up, alive cases with no survival time were excluded from analysis. Using SEER 2007 Multiple Primary and Histology Coding Rules, 4 we allowed for multiple primary cancers to be included for each patient, but only one record per patient was included in each survival estimate. For example, if a person had three primary tumors during the period , in the order of breast colon breast, then the first breast cancer case was used for breast cancer survival, the colon case was used for colon cancer survival, and the first breast cancer case was used for all sites. If a person had more than one tumor in a primary site category, but different stage, the first in each stage group was used in the stage-specific survival calculations. Likewise, if a person had more than one tumor in a primary site category, but different age group at diagnosis, the first in each age group was used in the age-specific survival calculations. Thus, the sum of the cases in the age-specific analyses exceeds the all ages count, and the sum of the cases in the stage-specific analyses exceeds the all stages count. Due to the impacts of hurricanes Katrina and Rita on populations in Alabama, Louisiana and Texas, data for diagnosis year 2005 were limited to cases diagnosed from January-June 2005 in these states. For other diagnosis years, all data were used. SEER*Stat (version 8.2.1) was used to perform the survival calculations. 5 Staff at Information Management Services, Inc. (Calverton, MD), prepared a SEER*Stat database for the purpose of calculating CINA Survival statistics. 6 The survival duration in months was calculated based on complete dates. For registries meeting SEER follow-up standards (SEER registries plus Montana and Wyoming), the survival duration for alive patients was calculated through the date of last contact (or study cutoff, if earlier). For the remaining registries, survival duration for alive patients was calculated through December 31, 2011, with all patients not known to be dead presumed to be alive on this date. Survival calculations were performed using the actuarial method on monthly intervals, and 60-month agestandardized relative survival ratios (RSR) are reported in the results. We calculated relative survival using the Ederer II method to compute expected survival. 7 The Ederer II method calculates the expected survival rates for patients under observation at each point of follow-up so the matched individuals are considered to be at risk until the corresponding cancer patient dies or is censored. Expected survival was estimated from life tables matched to the cancer patients by age, sex, year, and geographic area, and for the United States, also by race and socioeconomic status (SES). Details regarding the production of the U.S. life tables for expected survival will be forthcoming (Mariotto et al). 8 For Canada, official Statistics Canada life tables were used for all provinces and territories except Prince Edward Island. Because unabridged life tables were not available for this jurisdiction from Statistics Canada, modeled life tables from CONCORD-2 were utilized instead. 9 U.S. life tables included SES, while the Canadian life tables did not. It is not known what impact the different approaches to life table construction has on comparisons between U.S. and Canadian relative survival estimates. Cases were censored at an achieved age of 100 years. a For the SEER Behavior Recode for Analysis, the term malignant means the case had a behavior code of 3 (malignant) in both ICD-O-2 and ICD-O-3. In situ urinary bladder cases are included with malignant cases for cancer incidence reporting and are treated thusly in this report. INTRODUCTION AND TECHNICAL NOTES I-3

16 Because the excess mortality due to cancer is often age dependent, relative survival estimates were age standardized using the International Cancer Survival Standards (ICSS) and age groups 15-44, 45-54, 55-64, 65-74, and 75+ (see Table 1, Weights used in SEER*Stat using the Five Default s). 10 There are three ICSS age standards, depending on cancer site: (1) standard 1 for sites that have increasing incidence with age, (2) standard 2 for sites that have relatively consistent incidence by age, and (3) standard 3 for sites with higher incidence among younger adults. We used ICSS age standard 1 for All Sites combined, breast, colon & rectum, corpus & uterus, esophagus, kidney & renal pelvis, larynx, leukemia, liver & intrahepatic bile duct, lung & bronchus, mesothelioma, myeloma, non-hodgkin lymphoma, oral cavity & pharynx, ovary, pancreas, prostate, stomach, and urinary bladder. For prostate cancer, relative survival estimates were age standardized using the ICSS age standard 1 and age groups 15-54, 55-64, 65-74, 75-84, and 85+ with weights: 19, 23, 29, 23, and 6, respectively. We used ICSS age standard 2 for brain and other nervous system, cervix uteri, melanoma of the skin, and thyroid; and ICSS age standard 3 for Hodgkin lymphoma and testis. Survival statistics were not calculated if the number of cases was fewer than 10. If the number of cases was between 10 and 49, age standardization was not performed, and unstandardized RSRs were calculated (these are footnoted in the tables). If the number of cases was 50 or more, age-standardized RSRs were calculated unless: (1) there were no cases in one or more of the age groups, or a constituent age-specific RSR could not be calculated; (2) the width of the confidence interval for the age-standardized estimate was > 40 percentage points; or (3) the standard error of the age-standardized estimate was 10%. In those instances, unstandardized RSRs were used instead. Estimates of unstandardized RSRs were suppressed if the width of the confidence interval for the RSR was > 40 percentage points or the standard error for a RSR was 10%. If the last patient involved in a survival calculation is censored alive prior to 60 months, the RSR at 60 months is not defined. Table 1. ICSS Weights used in SEER*Stat using the Five Default s Age Standard for Survival Population Weights (15-44, 45-54, 55-64, 65-74, 75+) ICSS 1 ICSS 2 ICSS years years years years years RSRs can be more than 100% when the observed survival is higher than the expected survival (e.g., for localized staged prostate cancer). In these situations, RSRs were capped at 100%. If the RSR is greater than or equal to 100%, no confidence intervals are shown. If the RSR is less than 100%, but rounds to 100.0% in the tables (one decimal point), confidence intervals are shown. Cumulative relative survival can exceed the survival in the previous time interval when the observed survival decreases more slowly than the expected survival. In these situations, RSRs and standard errors were imputed using the values from the previous time interval. For 0% RSR, the standard error is not defined and the confidence interval is not calculable. Two sets of statistics for all sites combined are presented. The first is labeled All Sites and shows the agestandardized RSRs for all sites combined using the ICSS age standard 1. The All Sites survival statistics reflect the primary site distribution in each jurisdiction, so the RSR in Idaho may not be comparable to the RSR in Kentucky because Kentucky has higher rates of smoking-related cancers. The second is labeled All Sites (Standardized) and shows a composite survival index. The index is the weighted sum of the site-specific RSRs, with the weights derived from the proportionate distribution of NAACCR North American incidence counts for diagnosis years as reported for the November 2014 Call for Data. This range of years was selected because the incidence data are mature enough for reporting delay to be ignorable. Case counts to I-4 INTRODUCTION AND TECHNICAL NOTES

17 derive the weights were limited to ages 15 and older, malignant behavior (plus urinary bladder in situ), and the SEER area-based registries were excluded to avoid double counting for their respective states. The All Sites (Standardized) statistics are comparable between jurisdictions because they are standardized by age, sex, and primary site distribution (but not race). This type of index has been suggested for use as an indicator for cancer control. 11,12 For calculating the index, if a site-specific age-standardized RSR was not available for a jurisdiction, such as for rare cancers in smaller populations, the estimate was replaced with that of the country (United States or Canada) that contains the jurisdiction. This replacement was conducted by race for the United States (total, white, and Black tables). Confidence intervals for the index were calculated using the normal approximation on the log scale, as suggested in the Corazziari et al. paper. 5 There are more cases included in the All Sites (Standardized) category than for All Sites because only one case per person is included in All Sites, but a person could contribute one case each to many of the individual site categories in All Sites (Standardized). The confidence intervals for All Sites (Standardized) can be narrower than for All Sites because of the national replacement data and the larger numbers of cases. If more than 30% of the site-specific age-standardized RSR estimates were not available for a jurisdiction, and were replaced with that of the country, the All Sites (Standardized) estimate was suppressed. For tables presenting RSRs by stage, SEER Summary 2000 was derived from Collaborative. Results by stage for Canada include data from the Alberta, Manitoba, Newfoundland and Labrador, Nova Scotia, and Prince Edward Island registries. This represents 19.4% of the total Canadian population and 30.7% of the population contributing to the Canadian survival statistics in this volume. Results by stage for the United States include data from all registries. Results by stage are not presented for NAACCR North America combined. The race category white includes both white non-hispanics and white Hispanics. Pinheiro et al. have shown that in SEER data, Hispanics and Asians are more likely to have incomplete follow-up than non-hispanic whites or Blacks, and those with worse prognoses are more likely to have incomplete follow-up than those with better prognoses. 13 In addition, death ascertainment among Hispanics may be biased for all causes of death, not just cancer-related causes, so life tables for Hispanics may also be problematic. Because of these issues, the SAWG decided not to use life tables stratified by ethnicity and not to present survival statistics by ethnicity. Variation in survival by registry catchment area can be due to several factors, including but not limited to: (1) differences in demographic characteristics related to race, ethnicity, and SES; (2) cancer screening rates; (3) access to and quality of care; and (4) cancer registration practices that impact case ascertainment, date of diagnosis and follow-up. In registries for which survival time was calculated using the presumed alive method, survival may be positively biased. 14 The life tables currently available for calculating expected survival may not completely reflect all factors contributing to variation in all-cause mortality, such as smoking. Interpretation of the results should include these considerations. REFERENCES 1. Current SEER follow-up standards page C1. 2. Weir HK, Johnson CJ, Mariotto AB, Turner D, Wilson RJ, Nishri D, Ward KC. Evaluation of NAACCR Cancer in North America data for use in population-based cancer survival studies. J Natl Cancer Inst Monogr Nov;2014(49): doi: /jncimonographs/lgu SEER Behavior Code for Analysis. INTRODUCTION AND TECHNICAL NOTES I-5

18 4. SEER 2007 Multiple Primary and Histology Coding Rules SEER*Stat version 8.2.1; produced by the Surveillance Research Program of the Division of Cancer Control and Population Sciences, National Cancer Institute, and Information Management Services, Inc., Calverton, MD. 6. Surveillance, Epidemiology and End Results (SEER) Program ( SEER*Stat Database: NAACCR Incidence - CiNA Analytic File, , for Expanded Races, Custom File With County, Johnson - Survival WG, North American Association of Central Cancer Registries (SEER*Stat Database ID 41013). 7. Ederer F, Heise H (1959). Instructions to IBM 650 programmers in processing survival computations, methodological note 10. End Results Evaluation Section, National Cancer Institute. 8. Surveillance, Epidemiology, and End Results (SEER) Program ( SEER*Stat Database: Expected Survival - U.S. by race (W,B,AIAN,API) and Canada , Ages 0-99, Statecounty (modeled by varied state-county-ses), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch (SEER*Stat Database ID 01597). 9. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A et al. (2014). Global surveillance of cancer survival : analysis of individual data for patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. ISSN DOI: /S (14) Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer Oct;40(15): Verdecchia A, Baili P, Quaglia A, Kunkler I, Ciampichini R, Berrino F, Micheli A. Patient survival for all cancers combined as indicator of cancer control in Europe. Eur J Public Health Oct;18(5): doi: /eurpub/ckn022. Epub 2008 Apr Quaresma M, Coleman MP, Rachet B. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, : a population-based study. Lancet Mar 28;385(9974): doi: /S (14) Epub 2014 Dec Pinheiro PS, Morris CR, Liu L, Bungum TJ, Altekruse SF. The impact of follow-up type and missed deaths on population-based cancer survival studies for Hispanics and Asians. J Natl Cancer Inst Monogr Nov;2014(49): doi: /jncimonographs/lgu Johnson CJ, Weir HK, Yin D, Niu X. The Impact of Patient Follow-up on Population-based Survival Rates. J Registry Manag. 2010; 37(3): I-6 INTRODUCTION AND TECHNICAL NOTES

19 Section II Five Year Age-Standardized Relative Survival Ratios for Cancers Diagnosed , United States, Canada and North America Seattle Puget Sound Greater Bay Area Metro Detroit Los Angeles Washington D.C. Metro Atlanta Participating Registries

20

21 Complete Method, Follow-Up Through 2011 for All Races, All Sites NAACCR U.S. Combined Total 2,981, ,817, Race White 2,493, ,360, Black 331, , Localized 1,440, ,295, Regional 570, , Distant 730, , Unknown 255, , , * 314, * , * 469, * , * 631, * , * 629, * , * 788, * NAACCR Canadian Combined Total 355, , Localized 38, , Regional 21, , Distant 27, , Unknown 17, , , * 35, * , * 53, * , * 72, * , * 73, * , * 95, * NAACCR North America Combined Total 3,337, ,146, Localized 1,479, ,331, Regional 591, , Distant 757, , Unknown 273, , , * 350, * , * 523, * , * 703, * , * 703, * , * 883, * All Sites Combined Survival II-1

22 Complete Method, Follow-Up Through 2011 for All Races, Urinary Bladder (incl. in situ) NAACCR U.S. Combined Total 204, , Race White 188, , Black 9, , Localized 75, , Regional 14, , Distant 7, , Unknown 8, , , * 1, * , * 5, * , * 11, * , * 17, * , * 31, * NAACCR Canadian Combined Total 27, , Localized 1, Regional Distant Unknown 2, * * , * * , * 1, * , * 2, * , * 4, * NAACCR North America Combined Total 232, , Localized 77, , Regional 14, , Distant 7, , Unknown 10, , , * 1, * , * 6, * , * 13, * , * 19, * , * 35, * Urinary Bladder (incl. in situ) II-2 Combined Survival

23 Complete Method, Follow-Up Through 2011 for All Races, Brain & Other Nervous System NAACCR U.S. Combined Total 42, , Race White 38, , Black 2, , Localized 33, , Regional 6, , Distant Unknown 2, , , * 7, * , * 5, * , * 7, * , * 6, * 75+ 7, * 7, * NAACCR Canadian Combined Total 5, , Localized * Regional * Distant Unknown * * , * * * * , * * , * * * 1, * NAACCR North America Combined Total 48, , Localized 34, , Regional 6, , Distant Unknown 3, , , * 8, * , * 5, * , * 8, * , * 7, * 75+ 8, * 8, * Brain & Other Nervous System Combined Survival II-3

24 Complete Method, Follow-Up Through 2011 for All Races, Female Breast NAACCR U.S. Combined Total , Race White , Black , Localized , Regional , Distant , Unknown , , * , * , * , * , * NAACCR Canadian Combined Total , Localized , Regional - - 9, Distant - - 1, Unknown , * , * , * , * , * NAACCR North America Combined Total , Localized , Regional , Distant , Unknown , , * , * , * , * , * Female Breast II-4 Combined Survival

25 Complete Method, Follow-Up Through 2011 for All Races, Cervix Uteri NAACCR U.S. Combined Total , Race White , Black - - 8, Localized , Regional , Distant - - 6, Unknown - - 3, , * , * , * , * , * NAACCR Canadian Combined Total - - 6, Localized Regional Distant * Unknown , * , * , * * * NAACCR North America Combined Total , Localized , Regional , Distant - - 6, Unknown - - 3, , * , * , * , * , * Cervix Uteri Combined Survival II-5

26 Complete Method, Follow-Up Through 2011 for All Races, Colon & Rectum NAACCR U.S. Combined Total 295, , Race White 244, , Black 34, , Localized 121, , Regional 102, , Distant 59, , Unknown 17, , , * 14, * , * 35, * , * 51, * , * 62, * , * 115, * NAACCR Canadian Combined Total 48, , Localized 4, , Regional 6, , Distant 3, , Unknown 1, , * 1, * , * 4, * , * 7, * , * 9, * , * 17, * NAACCR North America Combined Total 343, , Localized 126, , Regional 108, , Distant 62, , Unknown 18, , , * 16, * , * 40, * , * 58, * , * 72, * , * 133, * Colon & Rectum II-6 Combined Survival

27 Complete Method, Follow-Up Through 2011 for All Races, Esophagus NAACCR U.S. Combined Total 48, , Race White 42, , Black 4, , Localized 10, , Regional 15, , Distant 18, , Unknown 5, , , * * , * 1, * , * 2, * , * 3, * , * 5, * NAACCR Canadian Combined Total 5, , Localized * * Regional * 98 - Distant Unknown * * * * , * * , * * 75+ 1, * * NAACCR North America Combined Total 54, , Localized 10, , Regional 15, , Distant 18, , Unknown 6, , , * * , * 1, * , * 3, * , * 3, * , * 6, * Esophagus Combined Survival II-7

28 Complete Method, Follow-Up Through 2011 for All Races, Kidney & Renal Pelvis NAACCR U.S. Combined Total 127, , Race White 108, , Black 13, , Localized 81, , Regional 21, , Distant 19, , Unknown 5, , , * 6, * , * 12, * , * 18, * , * 19, * , * 21, * NAACCR Canadian Combined Total 12, , Localized 1, , Regional * Distant * * Unknown 1, * * , * 1, * , * 1, * , * 1, * 75+ 2, * 2, * NAACCR North America Combined Total 140, , Localized 83, , Regional 22, , Distant 20, , Unknown 6, , , * 7, * , * 13, * , * 20, * , * 21, * , * 23, * Kidney & Renal Pelvis II-8 Combined Survival

29 Complete Method, Follow-Up Through 2011 for All Races, Larynx NAACCR U.S. Combined Total 40, , Race White 33, , Black 5, , Localized 22, , Regional 7, , Distant 7, , Unknown 2, , * * , * 1, * , * 2, * , * 2, * 75+ 8, * 2, * NAACCR Canadian Combined Total 3, Localized * Regional * Distant Unknown * * * , * * , * * * * NAACCR North America Combined Total 43, , Localized 23, , Regional 8, , Distant 7, , Unknown 2, , * * , * 1, * , * 3, * , * 3, * 75+ 9, * 2, * Larynx Combined Survival II-9

30 Complete Method, Follow-Up Through 2011 for All Races, Leukemias NAACCR U.S. Combined Total 91, , Race White 80, , Black 6, , Localized * Regional Distant 91, , Unknown , * 8, * , * 7, * , * 11, * , * 14, * , * 25, * NAACCR Canadian Combined Total 12, , Localized Regional Distant 3, , Unknown , * * , * * , * 1, * , * 1, * 75+ 3, * 3, * NAACCR North America Combined Total 103, , Localized * Regional Distant 94, , Unknown , * 9, * , * 8, * , * 13, * , * 16, * , * 28, * Leukemias II-10 Combined Survival

31 Complete Method, Follow-Up Through 2011 for All Races, Liver & Intrahepatic Bile Duct NAACCR U.S. Combined Total 69, , Race White 51, , Black 10, , Localized 29, , Regional 18, , Distant 12, , Unknown 9, , , * 1, * , * 3, * , * 6, * , * 6, * , * 9, * NAACCR Canadian Combined Total 5, , Localized * * Regional Distant Unknown * * * * * , * * , * * 75+ 1, * * NAACCR North America Combined Total 75, , Localized 29, , Regional 18, , Distant 12, , Unknown 10, , , * 1, * , * 3, * , * 6, * , * 7, * , * 10, * Liver & Intrahepatic Bile Duct Combined Survival II-11

32 Complete Method, Follow-Up Through 2011 for All Races, Lung & Bronchus NAACCR U.S. Combined Total 437, , Race White 370, , Black 50, , Localized 73, , Regional 102, , Distant 237, , Unknown 26, , , * 7, * , * 36, * , * 79, * , * 118, * , * 136, * NAACCR Canadian Combined Total 48, , Localized 1, , Regional 3, , Distant 8, , Unknown * * * , * 4, * , * 9, * , * 13, * , * 15, * NAACCR North America Combined Total 486, , Localized 75, , Regional 106, , Distant 246, , Unknown 27, , , * 8, * , * 40, * , * 88, * , * 131, * , * 152, * Lung & Bronchus II-12 Combined Survival